Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis

Journal of Affective Disorders
L A SmithCharles Bowden

Abstract

Our aim was to analyse existing data on the efficacy and tolerability of valproate for the treatment of acute bipolar depression. Randomized controlled trials comparing valproate with placebo were identified using searches of electronic databases in October 2008. Outcomes investigated were depression, anxiety, hypomania, attrition, and adverse events. Trial quality was assessed, and data were summarized using meta-analyses. Four randomized, controlled, doubleblind trials of 142 participants were included. Trial quality was good, although individual study sample sizes were small. Study duration was six weeks (2 studies) and eight weeks (2 studies). Meta-analysis showed a significant difference in favour of valproate for reduction in depressive symptoms, both on depression symptom scales (standardized mean difference (SMD) -0.35 (95% confidence interval, -0.69, -0.02)), and participants with at least 50% improvement in symptoms - relative risk (RR) 2.00 (1.13, 3.53). Effects on anxiety symptoms were small, SMD -0.32 (-0.72, 0.08) and inconclusive (p=0.12). No evidence of a difference in mania symptoms, withdrawal for any reason, lack of effectiveness or adverse events was detected. Nausea occurred more frequently with valproate c...Continue Reading

References

Jul 3, 1991·JAMA : the Journal of the American Medical Association·S YusufH A Tyroler
Jul 7, 2001·BMJ : British Medical Journal·P JüniM Egger
Mar 1, 2002·Journal of Affective Disorders·M E WinsbergT A Ketter
Jun 5, 2002·Archives of General Psychiatry·Lewis L JuddMartin B Keller
Feb 20, 2003·The Journal of Clinical Psychiatry·Robert M A HirschfeldKaren D Wagner
Jul 23, 2003·Journal of Psychopharmacology·G M Goodwin, UNKNOWN Consensus Group of the British Association for Psychopharmacology
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Nov 12, 2003·Archives of General Psychiatry·Mauricio TohenAlan Breier
May 18, 2004·The Australian and New Zealand Journal of Psychiatry·UNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder
Sep 1, 2004·The American Journal of Psychiatry·Harm J GijsmanGuy M Goodwin
Nov 24, 2004·The Journal of Clinical Psychiatry·Joseph R CalabreseMichael L Reed
Mar 23, 2005·Journal of Affective Disorders·Lori L DavisFrederick Petty
Jul 5, 2005·The Journal of the American Board of Family Practice·Robert M A HirschfeldCarol A Carlson
Jul 5, 2005·The American Journal of Psychiatry·Joseph R CalabreseJamie Mullen
Sep 15, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·J MorrowJ Craig
Apr 6, 2006·Statistics in Medicine·Michael J BradburnA Russell Localio
Nov 18, 2006·Journal of Clinical Psychopharmacology·Michael E ThaseUNKNOWN BOLDER II Study Group
Jan 22, 2008·Journal of Clinical Psychopharmacology·Michael E ThaseRandall Owen
Apr 18, 2008·Journal of Human Hypertension·M I Perez, V M Musini
Jan 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·John R GeddesGuy M Goodwin
Mar 3, 2009·Journal of Neurology·Torbjörn Tomson, Dina Battino
Apr 17, 2009·The New England Journal of Medicine·Kimford J MeadorUNKNOWN NEAD Study Group

❮ Previous
Next ❯

Citations

May 25, 2012·European Archives of Psychiatry and Clinical Neuroscience·Konstantinos N FountoulakisEduard Vieta
Feb 4, 2012·Amino Acids·Greice CalettiRosane Gomez
Feb 9, 2013·CNS Spectrums·Laura MusettiLiliana Dell'Osso
Aug 28, 2010·Journal of Biomedicine & Biotechnology·Sébastien ChateauvieuxMarc Diederich
Feb 6, 2013·BMC Medicine·Else EisingMichel D Ferrari
Mar 26, 2011·Annals of General Psychiatry·Konstantinos N FountoulakisZoltan Rihmer
Jul 23, 2013·Neurotoxicology and Teratology·Yunkyoung LeeChang-Joong Lee
Oct 20, 2015·Expert Opinion on Pharmacotherapy·Charles L Bowden, Vivek Singh
Sep 12, 2015·Expert Opinion on Drug Safety·Eva Maria PichlerMoritz Muehlbacher
Jun 19, 2013·Psychiatry and Clinical Neurosciences·Shigenobu KanbaUNKNOWN Committee for Treatment Guidelines of Mood Disorders, Japanese Society of Mood Disorders, 2012
Dec 15, 2015·Case Reports in Psychiatry·Kamini Vasudev, Priya Sharma
Apr 23, 2016·Pharmacology & Therapeutics·Hans O Kalkman, Dominik Feuerbach
Sep 21, 2013·European Journal of Pharmacology·Antonio SiniscalchiGiovambattista De Sarro
Dec 24, 2014·Journal of Affective Disorders·Mark A FryeSusannah J Tye
May 12, 2012·The International Journal of Neuropsychopharmacology·María ReinaresEduard Vieta
Sep 29, 2011·Journal of Affective Disorders·Mauricio TohenRoss J Baldessarini
Dec 9, 2015·The Australian and New Zealand Journal of Psychiatry·Gin S MalhiAjeet B Singh
Apr 15, 2017·Behavioural Brain Research·Isabel Vieira de Assis LimaAntônio Carlos Pinheiro de Oliveira
May 13, 2018·Fundamental & Clinical Pharmacology·Iat-Lon LeongYuk-Man Leung
Nov 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kathryn N FreelandKelli L Garrison
Apr 14, 2010·Der Nervenarzt·H Grunze, S Dargel
Mar 20, 2013·CNS Spectrums·Michael A Cerullo, Stephen M Strakowski
Jan 30, 2020·Natural Product Reports·Levi W EvansBradley S Ferguson
May 10, 2017·Clinical Drug Investigation·Gabriele SaniLeonardo Tondo
May 2, 2014·Expert Review of Neurotherapeutics·Cecilio AlamoPilar García-García
Dec 19, 2013·Clinical Trials : Journal of the Society for Clinical Trials·Andrew A NierenbergUNKNOWN Bipolar CHOICE Study Group
Sep 8, 2020·Expert Opinion on Drug Safety·Laura OrsoliniUmberto Volpe
Dec 1, 2010·Current Opinion in Psychiatry
Nov 17, 2021·Psychopharmacology·Miriam OlivolaNatascia Brondino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here